ArticleMediators of inflammation2026
ATOJIN: A Natural Products Mixture, Alleviates Atopic Dermatitis in DNCB-Induced NC/Nga Mice.
Article in Mediators of inflammation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- ATOJIN: A Natural Products Mixture, Alleviates Atopic Dermatitis in DNCB-Induced NC/Nga Mice.Mediators of inflammation · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Atopic dermatitis (AD) is a chronic, relapsing inflammatory skin disorder with increasing global prevalence. ATOJIN is a natural product composed of Phellodendron amurense Ruprecht (PAR), Schizonepeta tenuifolia (ST), Sophora flavescens (SF), Glycyrrhiza uralensis (GU), and Liriope platyphylla (LP), all known for their anti-inflammatory properties. This study aims to evaluate the therapeutic potential of ATOJIN in a 2,4-dinitrochlorobenzene (DNCB)-induced AD mouse model by assessing its effects on inflammation and immune regulation. The therapeutic efficacy of ATOJIN was evaluated through the analysis of white blood cell subtypes, serum immunoglobulin E (IgE) levels, pro-inflammatory cytokines, and histological assessments of inflammatory and mast cell infiltration, focusing on systemic immune modulation. ATOJIN effectively alleviated AD lesions and symptoms in DNCB-induced mice, demonstrating significant improvements in dermatitis scores, ear thickness, and spleen weight. It also reduced epidermal thickness and the infiltration of inflammatory and mast cells. Furthermore, ATOJIN modulated serum levels of IgE and pro-inflammatory cytokines, including interleukin (IL)-2, IL-4, IL-6, and tumor necrosis factor (TNF)-α, indicating systemic anti-inflammatory effects. These results suggest that ATOJIN mitigates AD symptoms by modulating inflammatory responses, and its efficacy, comparable to or even superior to that of the topical standard-of-care tacrolimus, highlights its potential as a promising standalone oral therapeutic agent for the systemic management of AD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.